The TKI plus InO-based therapy for newly diagnosed Ph+ ALL successfully met the efficacy end point, achieving an 81% MR3+ rate within 2 courses with limited cycles of InO. The modified schema 2 ...

Giredestrant significantly improved IDFS in ER-positive, HER2-negative early breast cancer, reducing recurrence or death risk by 30% compared to SOC endocrine therapy. Subgroup analyses showed ...

Aromatase inhibitors demonstrated superior disease-free survival and time to distant recurrence compared to SERMs in HR+/HER2+ early breast cancer. The benefits of aromatase inhibitors were consistent ...

The combination of talquetamab-tgvs and pomalidomide achieved an 85.7% objective response rate in relapsed/refractory multiple myeloma patients. Median progression-free survival was 25.8 months, with ...

Panelists discuss how real-world practice often diverges from guideline recommendations due to access barriers, toxicity ...

Quality of life emerges as a central theme, with panelists emphasizing that patient-reported outcomes and psychosocial ...

Panelists discuss how the next generation of targeted agents, including sunvozertinib, BLU-945, and antibody-drug conjugates, ...

Thoughtful sequencing not only maximizes overall survival but also minimizes unnecessary toxicity. Planning enables ...

The ACCESS trial shows mismatched unrelated donors can provide excellent outcomes, addressing racial disparities in donor ...

The LimiTEC trial explored teclistamab discontinuation in multiple myeloma, showing comparable outcomes to continuous therapy with a median PFS of 19.9 months. Fixed-duration therapy may reduce ...

During a live event, Yelena Y. Janjigian, MD, moderated a discussion on how to use PD-L1 CPS status when considering ...

XmAb819 demonstrated a manageable safety profile with primarily grade 1 or 2 cytokine release syndrome and no neurotoxicity in ccRCC patients. The trial involved 69 patients, with a 25% objective ...